VIDEO: ANX007 may prevent vision loss, preserve photoreceptors in geographic atrophy

CHICAGO — In this Healio Video Perspective from the AAO meeting, Rahul N. Khurana, MD, of Northern California Retina Vitreous Associates discusses phase 2 results for ANX007 for the treatment of geographic atrophy.

According to Khurana, in the phase 2 ARCHER clinical trial, ANX007 (Annexon Biosciences) prevented vision loss in geographic atrophy and protected retinal photoreceptors with C1q inhibition.

“We are really excited about the upcoming phase 3 clinical trial ARCHER 2 to see if we can replicate these results,” Khurana said.

Published by:

Sources/Disclosures

Collapse

Source:

Khurana RN, et al. Preservation of vision by ANX007: Clinical results and anatomical changes from the phase 2 ARCHER trial. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.

Disclosures:
Khurana reports receiving research support from Annexon Biosciences.

Read more about

This post was originally published on this site